[HTML][HTML] Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
[HTML][HTML] Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
K van den Berg, TN Glatt, M Vermeulen, F Little… - Scientific …, 2022 - ncbi.nlm.nih.gov
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).
K van den Berg, TN Glatt, M Vermeulen, F Little… - Scientific …, 2022 - europepmc.org
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).
K van den Berg, TN Glatt, M Vermeulen, F Little… - 2022 - crick.figshare.com
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).
K van den Berg, TN Glatt, M Vermeulen… - Scientific …, 2022 - search.ebscohost.com
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient trial).
K van den Berg, TN Glatt, M Vermeulen, F Little… - 2022 - cabidigitallibrary.org
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
K van den Berg, TN Glatt, M Vermeulen… - Scientific …, 2022 - ui.adsabs.harvard.edu
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
K van den Berg, TN Glatt, M Vermeulen… - Scientific …, 2022 - pubmed.ncbi.nlm.nih.gov
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).
K van den Berg, TN Glatt, M Vermeulen, F Little… - Scientific …, 2022 - europepmc.org
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
antiviral activity and early observational studies suggested benefit in reducing COVID-19 …
[HTML][HTML] Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
K van den Berg, TN Glatt, M Vermeulen, F Little… - Scientific …, 2022 - ncbi.nlm.nih.gov
Background There is a need for effective therapy for COVID-19 pneumonia. Convalescent
plasma has antiviral activity and early observational studies suggested benefit in reducing …
plasma has antiviral activity and early observational studies suggested benefit in reducing …